Casado, E., Rosas, J., Rubio-Terrés, C., Rubio-Rodríguez, D., Boolell, M., & Arístegui, I. (2023). Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain.

Casado, E., J. Rosas, C. Rubio-Terrés, D. Rubio-Rodríguez, M. Boolell, y I. Arístegui. Cost-effectiveness of Weekly Gastro-resistant Risedronate 35 Mg, Compared With Weekly Alendronate 70 Mg Tablets, in the Treatment of Postmenopausal Osteoporosis in Spain. 2023.

Casado, E., et al. Cost-effectiveness of Weekly Gastro-resistant Risedronate 35 Mg, Compared With Weekly Alendronate 70 Mg Tablets, in the Treatment of Postmenopausal Osteoporosis in Spain. 2023.